Loading…
Lobbying Spend
—
Filings
8
Firms Hired
1
Active Period
2017–2018
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Abuse Deterrent Access Act of 2018
2018 · third_quarter · Firm: ARENTFOX SCHIFF LLP
Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse deterrent legislation H.R. 6 (SUPPORT for Patients and Communities Act), provisions relating to HHS study on abuse deterrent formulations access barriers under Medicare H.R. 5582 (Abuse Deterrent Access Act of 2018), all provisions Pharmaceutical anti-opioid prodrug regulatory bill
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5582
SUPPORT for Patients and Communities Act
2018 · third_quarter · Firm: ARENTFOX SCHIFF LLP
Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse deterrent legislation H.R. 6 (SUPPORT for Patients and Communities Act), provisions relating to HHS study on abuse deterrent formulations access barriers under Medicare H.R. 5582 (Abuse Deterrent Access Act of 2018), all provisions Pharmaceutical anti-opioid prodrug regulatory bill
Client expense: — · Firm income: $10,000
Matched citations: H.R. 6
Abuse Deterrent Access Act of 2018
2018 · second_quarter · Firm: ARENTFOX SCHIFF LLP
Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse deterrent legislation H.R. 6 (SUPPORT for Patients and Communities Act), provisions relating to HHS study on abuse deterrent formulations access barriers under Medicare H.R. 5582 (Abuse Deterrent Access Act of 2018), all provisions Pharmaceutical anti-opioid prodrug regulatory bill
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5582
SUPPORT for Patients and Communities Act
2018 · second_quarter · Firm: ARENTFOX SCHIFF LLP
Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse deterrent legislation H.R. 6 (SUPPORT for Patients and Communities Act), provisions relating to HHS study on abuse deterrent formulations access barriers under Medicare H.R. 5582 (Abuse Deterrent Access Act of 2018), all provisions Pharmaceutical anti-opioid prodrug regulatory bill
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
2017 · third_quarter · Firm: ARENTFOX SCHIFF LLP
FDA regulation of opioid abuse deterrent formulations H.R. 2430 (FDA Reauthorization Act of 2017), provisions relating to drugs H.R. 2025 (Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017), all provisions
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2025
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: ARENTFOX SCHIFF LLP
FDA regulation of opioid abuse deterrent formulations H.R. 2430 (FDA Reauthorization Act of 2017), provisions relating to drugs H.R. 2025 (Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017), all provisions
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2430
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
2017 · second_quarter · Firm: ARENTFOX SCHIFF LLP
FDA regulation of opioid abuse deterrent formulations H.R. 2430 (FDA Reauthorization Act of 2017), provisions relating to drugs H.R. 2025 (Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017), all provisions
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2025
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: ARENTFOX SCHIFF LLP
FDA regulation of opioid abuse deterrent formulations H.R. 2430 (FDA Reauthorization Act of 2017), provisions relating to drugs H.R. 2025 (Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017), all provisions
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2430
Source: Senate LDA